The age of anxiety: Role of animal models of anxiolytic action in drug discovery

British Journal of Pharmacology

Volumn 164, Issue 4, 2011, Pages 1129-1161

  Cryan, John F ^a,b   Sweeney, Fabian F ^a  

^a UNIVERSITY COLLEGE CORK   (Ireland)

^b UNIVERSITY COLLEGE CORK   (Ireland)

Author keywords

animal models; animal tests; anxiety; anxiolytic drugs; approach avoidance test; elevated plus maze; light dark box; novel anxiolytics; preclinical; predictive validity

Indexed keywords

BARBITURIC ACID DERIVATIVE; BENZODIAZEPINE DERIVATIVE; BUSPIRONE; CHLORDIAZEPOXIDE; CITALOPRAM; CLOZAPINE; DESIPRAMINE; DOSULEPIN; FLUOXETINE; HALOPERIDOL; IMIPRAMINE; MOCLOBEMIDE; MORPHINE; ONDANSETRON; PAROXETINE; PEXACERFONT; PHENOBARBITAL; PRAZOSIN; PROGESTERONE; PROPRANOLOL; SEROTONIN 1A AGONIST; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; TALAGLUMETAD; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; VERUCERFONT; VESTIPITANT; VIGABATRIN; ZOLPIDEM;

ANXIETY DISORDER; BEHAVIOR CHANGE; CHEMICALLY INDUCED DISORDER; CONDITIONED REFLEX; DEFENSIVE MARBLE BURYING TEST; DEPRESSION; DISEASE MODEL; DRUG EFFICACY; DRUG TOLERABILITY; ENDOPHENOTYPE; EXPERIMENTAL TEST; FOUR PLATE TEST; GELLER SEIFTER TEST; GENERALIZED ANXIETY DISORDER; GENETIC MANIPULATION; GENETIC MODEL; HUMAN; INSTRUMENTAL CONDITIONING; LIGHT DARK BOX; MATERNAL DEPRIVATION; MAZE TEST; MIRROR CHAMBER TEST; NONHUMAN; OPEN FIELD TEST; PRIORITY JOURNAL; REVIEW; SEDATION; SIDE EFFECT; SOCIAL INTERACTION; SOCIAL ISOLATION; SOCIAL PHOBIA; STAIRCASE TEST; TASTE AVERSION; TRANQUILIZING ACTIVITY; UNSPECIFIED SIDE EFFECT; VOCALIZATION; VOGEL PUNISHED DRINKING TEST;

EID: 79960021127     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2011.01362.x     Document Type: Review

References (370)

1. Acevedo SF, Pfankuch T, Ohtsu H, Raber J, (2006). Anxiety and cognition in female histidine decarboxylase knockout (Hdc-/-) mice. Behav Brain Res 168: 92-99. (Pubitemid 43153771)
2. Adler A, (1954). Understanding Human Nature: The Psychology of Personality. Fawcett Books: New York.
3. Alonso J, Lépine J, (2007). Overview of key data from the European Study of the Epidemiology of Mental Disorders (ESEMeD). J Clin Psychiatry 68: s3-s9.
4. Alonso J, Angermeyer MC, Bernert S, Bruffaerts R, Brugha TS, Bryson H, et al,. (2004). Prevalence of mental disorders in Europe: results from the European Study of the Epidemiology of Mental Disorders (ESEMeD) project. Acta Psychiatr Scand Suppl 109: 21-27.
5. Amaral OB, Roesler R, (2008). Targeting the NMDA receptor for fear-related disorders. Recent Pat CNS Drug Discov 3: 166-178.
6. American Psychiatric Association (2000). Diagnostic and Statistical Manual of Mental Disorders DSM-IV-TR Fourth Edition 4th Ed. American Psychiatric Publishing: Washington, DC.
7. de Angelis L, (1996). Experimental anxiety and antidepressant drugs: the effects of moclobemide, a selective reversible MAO-A inhibitor, fluoxetine and imipramine in mice. Naunyn Schmiedebergs Arch Pharmacol 354: 379-383. (Pubitemid 26284506)
8. Ansorge MS, Zhou M, Lira A, Hen R, Gingrich JA, (2004). Early-life blockade of the 5-HT transporter alters emotional behavior in adult mice. Science 306: 879-881. (Pubitemid 39446998)
9. Aprison MH, Ferster CB, (1961). Neurochemical correlates of behavior II. Correlation of brain monoamine oxidase activity with behavioural changes after iproniazid and 5-hydroxytryptophan administration. J Neurochem 6: 350-357.
10. Arguello PA, Gogos JA, (2006). Modeling madness in mice: one piece at a time. Neuron 52: 179-196. (Pubitemid 44466363)
11. Aron C, Simon P, Larousse C, Boissier JR, (1971). Evaluation of a rapid technique for detecting minor tranquilizers. Neuropharmacology 10: 459-469.
12. Atack J, Wafford K, Street L, Dawson G, Tye S, Van Laere K, et al,. (2011). MRK-409 (MK-0343), a GABAA receptor subtype-selective partial agonist, is a non-sedating anxiolytic in preclinical species but causes sedation in humans. J Psychopharmacol 25: 314-328.
13. Auden WH, (1947). The Age of Anxiety: A Baroque Eclogue. Random House: New York.
14. Azevedo TM, Volchan E, Imbiriba LA, Rodrigues EC, Oliveira JM, Oliveira LF, et al,. (2005). A freezing-like posture to pictures of mutilation. Psychophysiology 42: 255-260. (Pubitemid 40839532)
15. Baldwin DS, Ajel KI, Garner M, (2010). Pharmacological treatment of generalized anxiety disorder. In:, Stein MB, Steckler T, (eds). Behavioral Neurobiology of Anxiety and Its Treatment. Current Topics in Behavioural Neurosciences. Springer-Verlag: Heidelberg, Germany, pp. 453-467.
16. Ballard TM, Woolley ML, Prinssen E, Huwyler J, Porter R, Spooren W, (2005). The effect of the mGlu5 receptor antagonist MPEP in rodent tests of anxiety and cognition: a comparison. Psychopharmacology (Berl) 179: 218-229. (Pubitemid 40576709)
17. Balon R, Pohl R, Yeragani VK, Rainey JM, Weinberg P, (1988). Lactate- and isoproterenol-induced panic attacks in panic disorder patients and controls. Psychiatry Res 23: 153-160. (Pubitemid 18065394)
18. Bannerman DM, Deacon RMJ, Offen S, Friswell J, Grubb M, Rawlins JNP, (2002). Double dissociation of function within the hippocampus: spatial memory and hyponeophagia. Behav Neurosci 116: 884-901.
19. Bannerman DM, Grubb M, Deacon RMJ, Yee BK, Feldon J, Rawlins JNP, (2003). Ventral hippocampal lesions affect anxiety but not spatial learning. Behav Brain Res 139: 197-213. (Pubitemid 36298503)
20. Barad M, (2005). Fear extinction in rodents: basic insight to clinical promise. Curr Opin Neurobiol 15: 710-715. (Pubitemid 41682313)
21. Barros M, Maior RS, Huston JP, Tomaz C, (2008). Predatory stress as an experimental strategy to measure fear and anxiety-related behaviors in non-human primates. Rev Neurosci 19: 157-169.
22. Becker ES, Rinck M, Margraf J, Roth WT, (2001). The emotional Stroop effect in anxiety disorders: general emotional or disorder specificity? J Anxiety Disord 15: 147-159. (Pubitemid 32577392)
23. Belzung C, Griebel G, (2001). Measuring normal and pathological anxiety-like behaviour in mice: a review. Behav Brain Res 125: 141-149. (Pubitemid 33000452)
24. Benvenga MJ, Overshiner CD, Monn JA, Leander JD, (1999). Disinhibitory effects of LY354740, a new mGluR2 agonist, on behaviors suppressed by electric shock in rats and pigeons. Drug Dev Res 47: 37-44. (Pubitemid 29293571)
25. BermÃdez-Rattoni F, Ramírez-Lugo L, Gutiérrez R, Miranda MI, (2004). Molecular signals into the insular cortex and amygdala during aversive gustatory memory formation. Cell Mol Neurobiol 24: 25-36. (Pubitemid 38233727)
26. Blanchard D, (2003). The mouse defense test battery: pharmacological and behavioral assays for anxiety and panic. Eur J Pharmacol 463: 97-116. (Pubitemid 36205074)
27. Blizard DA, Adams N, (2002). The Maudsley reactive and nonreactive strains: a new perspective. Behav Genet 32: 277-299. (Pubitemid 35192991)
28. Bodnoff SR, Suranyi-Cadotte B, Aitken DH, Quirion R, Meaney MJ, (1988). The effects of chronic antidepressant treatment in an animal model of anxiety. Psychopharmacology (Berl) 95: 298-302.
29. Bodnoff SR, Suranyi-Cadotte B, Quirion R, Meaney MJ, (1989). A comparison of the effects of diazepam versus several typical and atypical anti-depressant drugs in an animal model of anxiety. Psychopharmacology (Berl) 97: 277-279. (Pubitemid 19040176)
30. van Bogaert MJV, Groenink L, Oosting RS, Westphal KGC, van der Gugten J, Olivier B, (2006). Mouse strain differences in autonomic responses to stress. Genes Brain Behav 5: 139-149. (Pubitemid 43348555)
31. Boren JJ, Sidman M, Herrnstein RJ, (1959). Avoidance, escape, and extinction as functions of shock intensity. J Comp Physiol Psychol 52: 420-426.
32. Borsini F, Podhorna J, Marazziti D, (2002). Do animal models of anxiety predict anxiolytic-like effects of antidepressants? Psychopharmacology (Berl) 163: 121-141. (Pubitemid 35013604)
33. Bourin M, HascoÃt M, (2003). The mouse light/dark box test. Eur J Pharmacol 463: 55-65. (Pubitemid 36205072)
34. Bourin M, Redrobe JP, Hascoet M, Baker GB, Colombel MC, (1996). A schematic representation of the psychopharmacological profile of antidepressants. Prog Neuropsychopharmacol Biol Psychiatry 20: 1389-1402. (Pubitemid 26412842)
35. Bouwknecht JA, Paylor R, (2008). Pitfalls in the interpretation of genetic and pharmacological effects on anxiety-like behaviour in rodents. Behav Pharmacol 19: 385-402.
36. Bouwknecht JA, Olivier B, Paylor RE, (2007). The stress-induced hyperthermia paradigm as a physiological animal model for anxiety: a review of pharmacological and genetic studies in the mouse. Neurosci Biobehav Rev 31: 41-59. (Pubitemid 44880072)
37. Bradley BP, Mogg K, White J, Groom C, de Bono J, (1999). Attentional bias for emotional faces in generalized anxiety disorder. Br J Clin Psychol 38 (Pt 3): 267-278. (Pubitemid 29435634)
38. Bradwejn J, Koszycki D, (2001). Cholecystokinin and panic disorder: past and future clinical research strategies. Scand J Clin Lab Invest Suppl 234: 19-27. (Pubitemid 33043622)
39. Braun AA, Skelton MR, Vorhees CV, Williams MT, (2011). Comparison of the elevated plus and elevated zero mazes in treated and untreated male Sprague-Dawley rats: effects of anxiolytic and anxiogenic agents. Pharmacol Biochem Behav 97: 406-415.
40. Brocco M, Dekeyne A, Mannoury la Cour C, Touzard M, Girardon S, Veiga S, et al,. (2008). Cellular and behavioural profile of the novel, selective neurokinin1 receptor antagonist, vestipitant: a comparison to other agents. Eur Neuropsychopharmacol 18: 729-750.
41. Broekkamp CL, Rijk HW, Joly-Gelouin D, Lloyd KL, (1986). Major tranquillizers can be distinguished from minor tranquillizers on the basis of effects on marble burying and swim-induced grooming in mice. Eur J Pharmacol 126: 223-229. (Pubitemid 16016552)
42. Camp M, Norcross M, Whittle N, Feyder M, D'Hanis W, Yilmazer-Hanke D, et al,. (2009). Impaired Pavlovian fear extinction is a common phenotype across genetic lineages of the 129 inbred mouse strain. Genes Brain Behav 8: 744-752.
43. Carroll JC, Boyce-Rustay JM, Millstein R, Yang R, Wiedholz LM, Murphy DL, et al,. (2007). Effects of mild early life stress on abnormal emotion-related behaviors in 5-HTT knockout mice. Behav Genet 37: 214-222. (Pubitemid 46144057)
44. Carvalho-Netto E, (2004). Use of the elevated T-maze to study anxiety in mice. Behav Brain Res 148: 119-132. (Pubitemid 37543661)
45. Caspi A, McClay J, Moffitt TE, Mill J, Martin J, Craig IW, et al,. (2002). Role of genotype in the cycle of violence in maltreated children. Science 297: 851-854. (Pubitemid 34839638)
46. Caspi A, Sugden K, Moffitt TE, Taylor A, Craig IW, Harrington H, et al,. (2003). Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene. Science 301: 386-389. (Pubitemid 36877077)
47. Chandra D, Korpi ER, Miralles CP, De Blas AL, Homanics GE, (2005). GABAA receptor gamma 2 subunit knockdown mice have enhanced anxiety-like behavior but unaltered hypnotic response to benzodiazepines. BMC Neurosci 6: 30.
48. Charney DS, Heninger GR, Breier A, (1984). Noradrenergic function in panic anxiety. Effects of yohimbine in healthy subjects and patients with agoraphobia and panic disorder. Arch Gen Psychiatry 41: 751-763. (Pubitemid 14092253)
49. Chiu C, Brickley S, Jensen K, Southwell A, Mckinney S, Cull-Candy S, et al,. (2005). GABA transporter deficiency causes tremor, ataxia, nervousness, and increased GABA-induced tonic conductance in cerebellum. J Neurosci 25: 3234-3245. (Pubitemid 40463559)
50. Chojnacka-Wõjcik E, KÅodzinska A, Pilc A, (2001). Glutamate receptor ligands as anxiolytics. Curr Opin Investig Drugs 2: 1112-1119. (Pubitemid 32782621)
51. Commissaris RL, McCloskey TC, Harrington GM, Altman HJ, (1989). MR/Har and MNRA/Har Maudsley rat strains: differential response to chlordiazepoxide in a conflict task. Pharmacol Biochem Behav 32: 801-805. (Pubitemid 19162407)
52. Commissaris RL, Franklin L, Verbanac JS, Altman HJ, (1992). Maudsley reactive (MR/Har) and nonreactive (MNRA/Har) rats: performance in an operant conflict paradigm. Physiol Behav 52: 873-878.
53. Commissaris RL, Verbanac JS, Markovska VL, Altman HJ, Hill TJ, (1996). Anxiety-like and depression-like behavior in Maudsley reactive (MR) and non-reactive (NMRA) rats. Prog Neuropsychopharmacol Biol Psychiatry 20: 491-501. (Pubitemid 26168826)
54. Commissaris RL, Ardayfio PA, McQueen DA, Gilchrist GA, Overstreet DH, (2000). Conflict behavior and the effects of 8-OHDPAT treatment in rats selectively bred for differential 5-HT(1A)-induced hypothermia. Pharmacol Biochem Behav 67: 199-205.
55. Conley RK, Hutson PH, (2007). Effects of acute and chronic treatment with fluoxetine on stress-induced hyperthermia in telemetered rats and mice. Eur J Pharmacol 564: 138-145. (Pubitemid 46946859)
56. Conn PJ, Roth BL, (2008). Opportunities and challenges of psychiatric drug discovery: roles for scientists in academic, industry, and government settings. Neuropsychopharmacology 33: 2048-2060. (Pubitemid 351992094)
57. Cook MN, Bolivar VJ, McFadyen MP, Flaherty L, (2002). Behavioral differences among 129 substrains: implications for knockout and transgenic mice. Behav Neurosci 116: 600-611. (Pubitemid 34793381)
58. Coric V, Feldman HH, Oren DA, Shekhar A, Pultz J, Dockens RC, et al,. (2010). Multicenter, randomized, double-blind, active comparator and placebo-controlled trial of a corticotropin-releasing factor receptor-1 antagonist in generalized anxiety disorder. Depress Anxiety 27: 417-425.
59. Craft RM, Howard JL, Pollard GT, (1988). Conditioned defensive burying as a model for identifying anxiolytics. Pharmacol Biochem Behav 30: 775-780. (Pubitemid 19271167)
60. Crawley JN, (1981). Neuropharmacologic specificity of a simple animal model for the behavioral actions of benzodiazepines. Pharmacol Biochem Behav 15: 695-699. (Pubitemid 12195249)
61. Crawley JN, (2007). What's Wrong with My Mouse?: Behavioral Phenotyping of Transgenic and Knockout Mice. Wiley-Liss: New York.
62. Crawley JN, Davis LG, (1982). Baseline exploratory activity predicts anxiolytic responsiveness to diazepam in five mouse strains. Brain Res Bull 8: 609-612. (Pubitemid 13240601)
63. Crawley J, Goodwin FK, (1980). Preliminary report of a simple animal behavior model for the anxiolytic effects of benzodiazepines. Pharmacol Biochem Behav 13: 167-170. (Pubitemid 11225713)
64. Crawley JN, Belknap JK, Collins A, Crabbe JC, Frankel W, Henderson N, et al,. (1997). Behavioral phenotypes of inbred mouse strains: implications and recommendations for molecular studies. Psychopharmacology (Berl) 132: 107-124. (Pubitemid 27338986)
65. A-receptor clustering results in enhanced anxiety and a bias for threat cues. Nat Neurosci 2: 833-839. (Pubitemid 30491177)
66. Cryan JF, Holmes A, (2005). The ascent of mouse: advances in modelling human depression and anxiety. Nat Rev Drug Discov 4: 775-790. (Pubitemid 43090498)
67. Cryan JF, Kaupmann K, (2005). Don't worry 'B' happy!: a role for GABA(B) receptors in anxiety and depression. Trends Pharmacol Sci 26: 36-43. (Pubitemid 40052708)
68. Cryan JF, Slattery DA, (2007). Animal models of mood disorders: recent developments. Curr Opin Psychiatry 20: 1-7. (Pubitemid 44901068)
69. Cryan JF, Kelly PH, Chaperon F, Gentsch C, Mombereau C, Lingenhoehl K, et al,. (2004). Behavioral characterization of the novel GABAB receptor-positive modulator GS39783 (N,N'-dicyclopentyl-2-methylsulfanyl-5-nitro-pyrimidine-4,6- diamine): anxiolytic-like activity without side effects associated with baclofen or benzodiazepines. J Pharmacol Exp Ther 310: 952-963. (Pubitemid 39108915)
70. Cunha JM, Masur J, (1978). Evaluation of psychotropic drugs with a modified open field test. Pharmacology 16: 259-267. (Pubitemid 8288895)
71. Czech DA, Quock RM, (1993). Nitrous oxide induces an anxiolytic-like effect in the conditioned defensive burying paradigm, which can be reversed with a benzodiazepine receptor blocker. Psychopharmacology (Berl) 113: 211-216. (Pubitemid 24001994)
72. Darwin C, (1871). The Descent of Man. Penguin Classics: London.
73. Darwin C, (1872). The Expression of the Emotions in Man and Animals. General Books LLC: New York.
74. Davis M, (1990). Animal models of anxiety based on classical conditioning: the conditioned emotional response (CER) and the fear-potentiated startle effect. Pharmacol Ther 47: 147-165. (Pubitemid 20228577)
75. Davis M, Ressler K, Rothbaum BO, Richardson R, (2006). Effects of d-cycloserine on extinction: translation from preclinical to clinical work. Biol Psychiatry 60: 369-375. (Pubitemid 44215855)
76. Davis M, Walker DL, Miles L, Grillon C, (2010). Phasic vs sustained fear in rats and humans: role of the extended amygdala in fear vs anxiety. Neuropsychopharmacol 35: 105-135.
77. von Dawans B, Kirschbaum C, Heinrichs M, (2010). The trier social stress test for groups (TSST-G): a new research tool for controlled simultaneous social stress exposure in a group format. Psychoneuroendocrinology 36: 514-522.
78. Deacon RMJ, Rawlins JNP, (2005). Hippocampal lesions, species-typical behaviours and anxiety in mice. Behav Brain Res 156: 241-249. (Pubitemid 39576064)
79. De Angelis L, Furlan C, (2000). The anxiolytic-like properties of two selective MAOIs, moclobemide and selegiline, in a standard and an enhanced light/dark aversion test. Pharmacol Biochem Behav 65: 649-653. (Pubitemid 30182507)
80. De Boer SF, Koolhaas JM, (2003). Defensive burying in rodents: ethology, neurobiology and psychopharmacology. Eur J Pharmacol 463: 145-161. (Pubitemid 36205077)
81. Dekeyne A, Brocco M, Adhumeau A, Gobert A, Millan MJ, (2000). The selective serotonin (5-HT)1A receptor ligand, S15535, displays anxiolytic-like effects in the social interaction and Vogel models and suppresses dialysate levels of 5-HT in the dorsal hippocampus of freely-moving rats. A comparison with other anxiolytic agents. Psychopharmacology (Berl) 152: 55-66.
82. Dekeyne A, Mannoury la Cour C, Gobert A, Brocco M, Lejeune F, Serres F, et al,. (2008). S32006, a novel 5-HT2C receptor antagonist displaying broad-based antidepressant and anxiolytic properties in rodent models. Psychopharmacology (Berl) 199: 549-568.
83. Delgado MR, Olsson A, Phelps EA, (2006). Extending animal models of fear conditioning to humans. Biol Psychol 73: 39-48.
84. Depino AM, Tsetsenis T, Gross C, (2008). GABA homeostasis contributes to the developmental programming of anxiety-related behavior. Brain Res 1210: 189-199.
85. Depoortere H, Zivkovic B, Lloyd KG, Sanger DJ, Perrault G, Langer SZ, et al,. (1986). Zolpidem, a novel nonbenzodiazepine hypnotic. I. Neuropharmacological and behavioral effects. J Pharmacol Exp Ther 237: 649-658. (Pubitemid 16092830)
86. Dierssen M, GratacÃs M, SahÃn I, Martín M, Gallego X, Amador-Arjona A, et al,. (2006). Transgenic mice overexpressing the full-length neurotrophin receptor TrkC exhibit increased catecholaminergic neuron density in specific brain areas and increased anxiety-like behavior and panic reaction. Neurobiol Dis 24: 403-418. (Pubitemid 44592571)
87. DiMasi JA, Hansen RW, Grabowski HG, (2003). The price of innovation: new estimates of drug development costs. J Health Econ 22: 151-185. (Pubitemid 36279392)
88. Doggrell SA, (2003). Does the melanin-concentrating hormone antagonist SNAP-7941 deserve 3As? Expert Opin Investig Drugs 12: 1035-1038. (Pubitemid 36722455)
89. Dulawa SC, Hen R, (2005). Recent advances in animal models of chronic antidepressant effects: the novelty-induced hypophagia test. Neurosci Biobehav Rev 29: 771-783. (Pubitemid 40762599)
90. Dunayevich E, Erickson J, Levine L, Landbloom R, Schoepp DD, Tollefson GD, (2008). Efficacy and tolerability of an mGlu2/3 agonist in the treatment of generalized anxiety disorder. Neuropsychopharmacology 33: 1603-1610. (Pubitemid 351684700)
91. Duvoisin RM, Pfankuch T, Wilson JM, Grabell J, Chhajlani V, Brown DG, et al,. (2010). Acute pharmacological modulation of mGluR8 reduces measures of anxiety. Behav Brain Res 212: 168-173.
92. Ebner K, Singewald N, (2006). The role of substance P in stress and anxiety responses. Amino Acids 31: 251-272. (Pubitemid 44537051)
93. Ebner K, Sartori SB, Singewald N, (2009). Tachykinin receptors as therapeutic targets in stress-related disorders. Curr Pharm Des 15: 1647-1674.
94. Ehninger D, Silva AJ, (2010). Increased levels of anxiety-related behaviors in a tsc2 dominant negative transgenic mouse model of tuberous sclerosis. Behav Genet [Epub ahead of print] doi:10.1007/s10519-010-9398-1.
95. Ehrlich I, Humeau Y, Grenier F, Ciocchi S, Herry C, Lüthi A, (2009). Amygdala inhibitory circuits and the control of fear memory. Neuron 62: 757-771.
96. Eisener-Dorman AF, Lawrence DA, Bolivar VJ, (2010). Behavioral and genetic investigations of low exploratory behavior in Il18r1(-/-) mice: we can't always blame it on the targeted gene. Brain Behav Immun 24: 1116-1125.
97. Ervin GN, Cooper BR, (1988). Use of conditioned taste aversion as a conflict model: effects of anxiolytic drugs. J Pharmacol Exp Ther 245: 137-146.
98. Erzegovesi S, Martucci L, Henin M, Bellodi L, (2001). Low versus standard dose mCPP challenge in obsessive-compulsive patients. Neuropsychopharmacology 24: 31-36.
99. Eser D, Schüle C, Baghai T, Floesser A, Krebs-Brown A, Enunwa M, et al,. (2007). Evaluation of the CCK-4 model as a challenge paradigm in a population of healthy volunteers within a proof-of-concept study. Psychopharmacology (Berl) 192: 479-487. (Pubitemid 46870744)
100. España J, Giménez-Llort L, Valero J, Miñano A, Rábano A, Rodriguez-Alvarez J, et al,. (2010). Intraneuronal beta-amyloid accumulation in the amygdala enhances fear and anxiety in Alzheimer's disease transgenic mice. Biol Psychiatry 67: 513-521.
101. Farrell WJ, Alberts JR, (2002). Stimulus control of maternal responsiveness to norway rat (Rattus norvegicus) pup ultrasonic vocalizations. J Comp Psychol 116: 297-307.
102. Fendt M, Fanselow MS, (1999). The neuroanatomical and neurochemical basis of conditioned fear. Neurosci Biobehav Rev 23: 743-760. (Pubitemid 29282023)
103. Fendt M, Schmid S, Thakker DR, Jacobson LH, Yamamoto R, Mitsukawa K, et al,. (2008). mGluR7 facilitates extinction of aversive memories and controls amygdala plasticity. Mol Psychiatry 13: 970-979.
104. File SE, (1980). The use of social interaction as a method for detecting anxiolytic activity of chlordiazepoxide-like drugs. J Neurosci Methods 2: 219-238. (Pubitemid 10050361)
105. Filip M, Baran L, Siwanowicz J, Chojnacka-Wõjcik E, PrzegaliÅski E, (1992). The anxiolytic-like effects of 5-hydroxytryptamine3 (5-HT3) receptor antagonists. Pol J Pharmacol Pharm 44: 261-269.
106. Finger BC, Dinan TG, Cryan JF, (2010). Leptin-deficient mice retain normal appetitive spatial learning yet exhibit marked increases in anxiety-related behaviours. Psychopharmacology (Berl) 210: 559-568.
107. Finn DA, Rutledge-Gorman MT, Crabbe JC, (2003). Genetic animal models of anxiety. Neurogenetics 4: 109-135. (Pubitemid 36612195)
108. Frantz S, (2004). Therapeutic area influences drug development costs. Nat Rev Drug Discov 3: 466-467. (Pubitemid 38807511)
109. Freud S, (1966). Introductory Lectures on Psychoanalysis Standard Edition. Liveright: New York.
110. van Gaalen MM, Stenzel-Poore MP, Holsboer F, Steckler T, (2002). Effects of transgenic overproduction of CRH on anxiety-like behaviour. Eur J Neurosci 15: 2007-2015. (Pubitemid 35471889)
111. Gatch MB, (2003). Discriminative stimulus effects of m- chlorophenylpiperazine as a model of the role of serotonin receptors in anxiety. Life Sci 73: 1347-1367. (Pubitemid 36798125)
112. Geller I, Seifter S, (1960). The effects of meprobamate, barbiturate, d-amphetamine and promazine on experimentally induced conflict in the rat. Psychopharmacologia 1: 482-492.
113. Geller I, Seifter J, (1962). The effects of mono-urethans, di-urethans and barbiturates on a punishment discrimination. J Pharmacol Exp Ther 136: 284-288.
114. Geller EB, Kulak JT, Seifter J, (1962). The effects of chlordiazepoxide and chlorpromazine on a punishment discrimination. Psychopharmacologia 3: 374-385.
115. George ED, Bordner KA, Elwafi HM, Simen AA, (2010). Maternal separation with early weaning: a novel mouse model of early life neglect. BMC Neurosci 11: 123.
116. Geyer MA, Markou A, (2000). Animal models of psychiatric disorders. In:, Bloom FE, Kupfer DJ, (eds). Psychophamacology: The Fourth Generation of Progress. Raven: New York, pp. 787-798.
117. Geyer MA, Markou A, (2002). The role of preclinical models in the development of psychotropic drugs. In:, Davis KL, Charney DS, Coyle JT, Nemeroff CB, (eds). Neuropsychopharmacology: The Fifth Generation of Progress. Lippincott Williams & Wilkins: New York, p. 445.
118. Goddyn H, Callaerts-Vegh Z, Stroobants S, Dirikx T, Vansteenwegen D, Hermans D, et al,. (2008). Deficits in acquisition and extinction of conditioned responses in mGluR7 knockout mice. Neurobiol Learn Mem 90: 103-111.
119. Gogos JA, Morgan M, Luine V, Santha M, Ogawa S, Pfaff D, et al,. (1998). Catechol-O-methyltransferase-deficient mice exhibit sexually dimorphic changes in catecholamine levels and behavior. Proc Natl Acad Sci U S A 95: 9991-9996. (Pubitemid 28415282)
120. Goldberg ME, Manian AA, Efron DH, (1967). A comparative study of certain pharmacologic responses following acute and chronic administrations of chlordiazepoxide. Life Sci 6: 481-491.
121. Goldberg AM, Zurlo J, Rudacille D, (1996). The three Rs and biomedical research. Science 272: 1403. (Pubitemid 26199983)
122. Gomez-Mancilla B, Marrer E, Kehren J, Kinnunen A, Imbert G, Hillebrand R, et al,. (2005). Central nervous system drug development: an integrative biomarker approach toward individualized medicine. NeuroRx 2: 683-695. (Pubitemid 41393275)
123. Gottesman II, Gould TD, (2003). The endophenotype concept in psychiatry: etymology and strategic intentions. Am J Psychiatry 160: 636-645. (Pubitemid 41079594)
124. Graeff FG, Netto CF, Zangrossi H, (1998). The elevated T-maze as an experimental model of anxiety. Neurosci Biobehav Rev 23: 237-246. (Pubitemid 29011625)
125. Graeff FG, Parente A, Del-Ben CM, Guimarães FS, (2003). Pharmacology of human experimental anxiety. Braz J Med Biol Res 36: 421-432. (Pubitemid 36592145)
126. Graham BM, Langton JM, Richardson R, (2010). Pharmacological enhancement of fear reduction: preclinical models. Br J Pharmacol 164: 1230-1247.
127. Griebel G, Blanchard DC, Agnes RS, Blanchard RJ, (1995a). Differential modulation of antipredator defensive behavior in Swiss-Webster mice following acute or chronic administration of imipramine and fluoxetine. Psychopharmacology (Berl) 120: 57-66.
128. Griebel G, Blanchard D, Jung A, Blanchard R, (1995b). A model of 'antipredator' defense in Swiss-Webster mice: effects of benzodiazepine receptor ligands with different intrinsic activities. Behav Pharmacol 6: 732-745.
129. Griebel G, Rodgers RJ, Perrault G, Sanger DJ, (1999). Behavioural profiles in the mouse defence test battery suggest anxiolytic potential of 5-HT(1A) receptor antagonists. Psychopharmacology (Berl) 144: 121-130. (Pubitemid 29264427)
130. Griebel G, Belzung C, Perrault G, Sanger DJ, (2000). Differences in anxiety-related behaviours and in sensitivity to diazepam in inbred and outbred strains of mice. Psychopharmacology 148: 164-170. (Pubitemid 30104138)
131. Grillon C, (2002). Startle reactivity and anxiety disorders: aversive conditioning, context, and neurobiology. Biol Psychiatry 52: 958-975. (Pubitemid 35356354)
132. Grillon C, (2008). Models and mechanisms of anxiety: evidence from startle studies. Psychopharmacology (Berl) 199: 421-437.
133. Groenink L, Verdouw PM, van Oorschot R, Olivier B, (2008). Models of anxiety: ultrasonic vocalizations of isolated rat pups. In:, Enna S, Williams M, Barret JF, Ferkany JW, Kenakin T, Porsolt RD, (eds). Current Protocols in Pharmacology. John Wiley & Sons: Hoboken, NJ DOI: 10.1002/0471141755. ph0518s43.
134. Gross C, Santarelli L, Brunner D, Zhuang X, Hen R, (2000). Altered fear circuits in 5-HT(1A) receptor KO mice. Biol Psychiatry 48: 1157-1163. (Pubitemid 32008441)
135. Gross C, Zhuang X, Stark K, Ramboz S, Oosting R, Kirby L, et al,. (2002). Serotonin1A receptor acts during development to establish normal anxiety-like behaviour in the adult. Nature 416: 396-400. (Pubitemid 34272867)
136. Guitton MJ, Dudai Y, (2004). Anxiety-like state associates with taste to produce conditioned taste aversion. Biol Psychiatry 56: 901-904. (Pubitemid 39575467)
137. Hall C, (1934). Emotional behavior in the rat. I. Defecation and urination as measures of individual differences in emotionality. J Comp Psychol 18: 385-403.
138. Handley SL, Mithani S, (1984). Effects of alpha-adrenoceptor agonists and antagonists in a maze-exploration model of 'fear'-motivated behaviour. Naunyn Schmiedebergs Arch Pharmacol 327: 1-5. (Pubitemid 14061582)
139. Hanson D, (2005). Librium. Chem Eng News 83: 80.
140. Härter MC, Conway KP, Merikangas KR, (2003). Associations between anxiety disorders and physical illness. Eur Arch Psychiatry Clin Neurosci 253: 313-320. (Pubitemid 38075973)
141. HascoÃt M, Bourin M, Nic Dhonnchadha BA, (2000a). The influence of buspirone, and its metabolite 1-PP, on the activity of paroxetine in the mouse light/dark paradigm and four plates test. Pharmacol Biochem Behav 67: 45-53.
142. HascoÃt M, Bourin M, Colombel MC, Fiocco AJ, Baker GB, (2000b). Anxiolytic-like effects of antidepressants after acute administration in a four-plate test in mice. Pharmacol Biochem Behav 65: 339-344. (Pubitemid 30100282)
143. Hasegawa S, Furuichi T, Yoshida T, Endoh K, Kato K, Sado M, et al,. (2009). Transgenic up-regulation of alpha-CaMKII in forebrain leads to increased anxiety-like behaviors and aggression. Mol Brain 2: 6.
144. Hashimoto H, Saito TR, Furudate S, Takahashi KW, (2001). Prolactin levels and maternal behavior induced by ultrasonic vocalizations of the rat pup. Exp Anim 50: 307-312. (Pubitemid 33620394)
145. Hasler G, Drevets WC, Manji HK, Charney DS, (2004). Discovering endophenotypes for major depression. Neuropsychopharmacology 29: 1765-1781. (Pubitemid 39336788)
146. Haubensak W, Kunwar PS, Cai H, Ciocchi S, Wall NR, Ponnusamy R, et al,. (2010). Genetic dissection of an amygdala microcircuit that gates conditioned fear. Nature 468: 270-276.
147. Heck S, Qian X, Velleca M, (2004). Genetically engineered mouse models for drug discovery: new chemical genetic approaches. Curr Drug Discov Technol 1: 13-26.
148. Hefner K, Whittle N, Juhasz J, Norcross M, Karlsson R, Saksida LM, et al,. (2008). Impaired fear extinction learning and cortico-amygdala circuit abnormalities in a common genetic mouse strain. J Neurosci 28: 8074-8085.
149. Heinrichs SC, Min H, Tamraz S, Carmouché M, Boehme SA, Vale WW, (1997). Anti-sexual and anxiogenic behavioral consequences of corticotropin-releasing factor overexpression are centrally mediated. Psychoneuroendocrinology 22: 215-224. (Pubitemid 27305565)
150. Heisler LK, Chu HM, Brennan TJ, Danao JA, Bajwa P, Parsons LH, et al,. (1998). Elevated anxiety and antidepressant-like responses in serotonin 5-HT1A receptor mutant mice. Proc Natl Acad Sci U S A 95: 15049-15054. (Pubitemid 29003754)
151. Heldt SA, Davis M, Ratti E, Corsi M, Trist D, Ressler KJ, (2009). Anxiolytic-like effects of the neurokinin 1 receptor antagonist GR-205171 in the elevated plus maze and contextual fear-potentiated startle model of anxiety in gerbils. Behav Pharmacol 20: 584-595.
152. Helton DR, Tizzano JP, Monn JA, Schoepp DD, Kallman MJ, (1998). Anxiolytic and side-effect profile of LY354740: a potent, highly selective, orally active agonist for group II metabotropic glutamate receptors. J Pharmacol Exp Ther 284: 651-660. (Pubitemid 28086655)
153. Herry C, Ciocchi S, Senn V, Demmou L, Müller C, Lüthi A, (2008). Switching on and off fear by distinct neuronal circuits. Nature 454: 600-606.
154. Hoffman EJ, Mathew SJ, (2008). Anxiety disorders: a comprehensive review of pharmacotherapies. Mt Sinai J Med 75: 248-262.
155. Hogg S, (1996). A review of the validity and variability of the elevated plus-maze as an animal model of anxiety. Pharmacol Biochem Behav 54: 21-30. (Pubitemid 26146661)
156. Holden C, (2010). Psychiatry. Behavioral addictions debut in proposed DSM-V. Science 327: 935.
157. Holmes A, (2001). Targeted gene mutation approaches to the study of
158. Holmes A, Cryan JF, (2006). Measuring anxiety- and depression-related behaviors in the mouse. In:, Fisch GS, Flint J, (eds). Transgenic and Knockout Models of Neuropsychiatric Disorders. Human Press: New York, NY, pp. 237-264.
159. Holmes A, Rodgers RJ, (1998). Responses of Swiss-Webster mice to repeated plus-maze experience: further evidence for a qualitative shift in emotional state? Pharmacol Biochem Behav 60: 473-488. (Pubitemid 28282689)
160. Holmes A, Iles JP, Mayell SJ, Rodgers RJ, (2001). Prior test experience compromises the anxiolytic efficacy of chlordiazepoxide in the mouse light/dark exploration test. Behav Brain Res 122: 159-167. (Pubitemid 32396771)
161. Homanics GE, Harrison NL, Quinlan JJ, Krasowski MD, Rick CE, de Blas AL, et al,. (1999). Normal electrophysiological and behavioral responses to ethanol in mice lacking the long splice variant of the gamma2 subunit of the gamma-aminobutyrate type A receptor. Neuropharmacology 38: 253-265. (Pubitemid 29073545)
162. Hughes RN, (1972). Chlordiazepoxide modified exploration in rats. Psychopharmacologia 24: 462-469.
163. Jacobson LH, Cryan JF, (2007). Feeling strained? Influence of genetic background on depression-related behavior in mice: a review. Behav Genet 37: 171-213. (Pubitemid 46150858)
164. Jacobson LH, Cryan JF, (2010). Genetic approaches to modeling anxiety in animals. In:, Stein MB, Steckler T, (eds). Behavioral Neurobiology of Anxiety and Its Treatment. Current Topics in Behavioural Neurosciences. Springer-Verlag: Heidelberg, Germany, pp. 161-201.
165. Jacobson LH, Kelly PH, Bettler B, Kaupmann K, Cryan JF, (2006). GABA(B(1)) receptor isoforms differentially mediate the acquisition and extinction of aversive taste memories. J Neurosci 26: 8800-8803. (Pubitemid 44319414)
166. Jacobson LH, Bettler B, Kaupmann K, Cryan JF, (2007). Behavioral evaluation of mice deficient in GABA(B(1)) receptor isoforms in tests of unconditioned anxiety. Psychopharmacology (Berl) 190: 541-553. (Pubitemid 46204471)
167. Joel D, (2006). Current animal models of obsessive compulsive disorder: a critical review. Prog Neuropsychopharmacol Biol Psychiatry 30: 374-388.
168. Johnson MP, Barda D, Britton TC, Emkey R, Hornback WJ, Jagdmann GE, et al,. (2005). Metabotropic glutamate 2 receptor potentiators: receptor modulation, frequency-dependent synaptic activity, and efficacy in preclinical anxiety and psychosis model(s). Psychopharmacology (Berl) 179: 271-283. (Pubitemid 40576715)
169. Johnson PL, Truitt WA, Fitz SD, Lowry CA, Shekhar A, (2008). Neural pathways underlying lactate-induced panic. Neuropsychopharmacology 33: 2093-2107. (Pubitemid 351992091)
170. Jones MW, (2002). A comparative review of rodent prefrontal cortex and working memory. Curr Mol Med 2: 639-647. (Pubitemid 35256295)
171. Jones BJ, Costall B, Domeney AM, Kelly ME, Naylor RJ, Oakley NR, et al,. (1988). The potential anxiolytic activity of GR38032F, a 5-HT3-receptor antagonist. Br J Pharmacol 93: 985-993. (Pubitemid 18093410)
172. Joyner AL, Sedivy JM, (2000). Gene Targeting: A Practical Approach, 2nd edn. Oxford University Press: Oxford.
173. Jung ME, Lal H, Gatch MB, (2002). The discriminative stimulus effects of pentylenetetrazol as a model of anxiety: recent developments. Neurosci Biobehav Rev 26: 429-439. (Pubitemid 36158661)
174. Kahn RS, Wetzler S, Asnis GM, Kling MA, Suckow RF, Praag HM, (1990). Effects of m-chlorophenylpiperazine in normal subjects: a dose-response study. Psychopharmacology 100: 339-344. (Pubitemid 20052421)
175. Kalueff AV, Tuohimaa P, (2005). The Suok ('ropewalking') murine test of anxiety. Brain Res Brain Res Protoc 14: 87-99. (Pubitemid 40249949)
176. Kalueff AV, Keisala T, Minasyan A, Tuohimaa P, (2007). Pharmacological modulation of anxiety-related behaviors in the murine Suok test. Brain Res Bull 74: 45-50. (Pubitemid 47187912)
177. Kalueff AV, Keisala T, Minasyan A, Kumar SR, LaPorte JL, Murphy DL, et al,. (2008). The regular and light-dark Suok tests of anxiety and sensorimotor integration: utility for behavioral characterization in laboratory rodents. Nat Protoc 3: 129-136.
178. Kantor S, Anheuer ZE, Bagdy G, (2000). High social anxiety and low aggression in Fawn-Hooded rats. Physiol Behav 71: 551-557. (Pubitemid 32184780)
179. Karolyi IJ, Burrows HL, Ramesh TM, Nakajima M, Lesh JS, Seong E, et al,. (1999). Altered anxiety and weight gain in corticotropin-releasing hormone-binding protein-deficient mice. Proc Natl Acad Sci U S A 96: 11595-11600. (Pubitemid 29487426)
180. Kash SF, Tecott LH, Hodge C, Baekkeskov S, (1999). Increased anxiety and altered responses to anxiolytics in mice deficient in the 65 kDa isoform of glutamic acid decarboxylase. Proc Natl Acad Sci U S A 96: 1698-1703. (Pubitemid 29098514)
181. Kehne J, De Lombaert S, (2002). Non-peptidic CRF1 receptor antagonists for the treatment of anxiety, depression and stress disorders. Curr Drug Targets CNS Neurol Disord 1: 467-493.
182. Kellner M, Muhtz C, Stark K, Yassouridis A, Arlt J, Wiedemann K, (2005). Effects of a metabotropic glutamate(2/3) receptor agonist (LY544344/LY354740) on panic anxiety induced by cholecystokinin tetrapeptide in healthy humans: preliminary results. Psychopharmacology (Berl) 179: 310-315. (Pubitemid 40576719)
183. Kessler RC, (2007). The global burden of anxiety and mood disorders: putting the European Study of the Epidemiology of Mental Disorders (ESEMeD) findings into perspective. J Clin Psychiatry 68 (Suppl. 2): 10-19. (Pubitemid 46333561)
184. Kessler RC, Merikangas KR, (2004). The national comorbidity survey replication (NCS-R): background and aims. Int J Methods Psychiatr Res 13: 60-68. (Pubitemid 39199021)
185. Kessler RC, Berglund P, Demler O, Jin R, Merikangas KR, Walters EE, (2005a). Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the national comorbidity survey replication. Arch Gen Psychiatry 62: 593-602. (Pubitemid 40973434)
186. Kessler RC, Chiu WT, Demler O, Merikangas KR, Walters EE, (2005b). Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the national comorbidity survey replication. Arch Gen Psychiatry 62: 617-627. (Pubitemid 40973437)
187. King JA, Messenger T, Ferris CF, (2002). Seed finding in golden hamsters: a potential animal model for screening anxiolytic drugs. Neuropsychobiology 45: 150-155. (Pubitemid 34458108)
188. Kirschbaum C, Pirke KM, Hellhammer DH, (1993). The 'trier social stress test'- a tool for investigating psychobiological stress responses in a laboratory setting. Neuropsychobiology 28: 76-81. (Pubitemid 23283755)
189. Klemenhagen KC, Gordon JA, David DJ, Hen R, Gross CT, (2006). Increased fear response to contextual cues in mice lacking the 5-HT1A receptor. Neuropsychopharmacology 31: 101-111. (Pubitemid 43250945)
190. KÅodziÅska A, Chojnacka-Wõjcik E, PaÅucha A, BraÅski P, Popik P, Pilc A, (1999). Potential anti-anxiety, anti-addictive effects of LY 354740, a selective group II glutamate metabotropic receptors agonist in animal models. Neuropharmacology 38: 1831-1839. (Pubitemid 29509721)
191. Kobayashi S, Ohta M, Miyasaka K, Funakoshi A, (1996). Decrease in exploratory behavior in naturally occurring cholecystokinin (CCK)-A receptor gene knockout rats. Neurosci Lett 214: 61-64. (Pubitemid 26273989)
192. Koike H, Ibi D, Mizoguchi H, Nagai T, Nitta A, Takuma K, et al,. (2009). Behavioral abnormality and pharmacologic response in social isolation-reared mice. Behav Brain Res 202: 114-121.
193. Kolber BJ, Boyle MP, Wieczorek L, Kelley CL, Onwuzurike CC, Nettles SA, et al,. (2010). Transient early-life forebrain corticotropin-releasing hormone elevation causes long-lasting anxiogenic and despair-like changes in mice. J Neurosci 30: 2571-2581.
194. Koszycki D, Bradwejn J, Bourin M, (1991). Comparison of the effects of cholecystokinin-tetrapeptide and carbon dioxide in health volunteers. Eur Neuropsychopharmacol 1: 137-141.
195. Kromer SA, Kessler MS, Milfay D, Birg IN, Bunck M, Czibere L, et al,. (2005). Identification of glyoxalase-I as a protein marker in a mouse model of extremes in trait anxiety. J Neurosci 25: 4375-4384. (Pubitemid 40628782)
196. Kronenberg G, Berger P, Tauber RF, Bandelow B, Henkel V, Heuser I, (2005). Randomized, double-blind study of SR142801 (osanetant). A novel neurokinin-3 (NK3) receptor antagonist in panic disorder with pre- and posttreatment cholecystokinin tetrapeptide (CCK-4) challenges. Pharmacopsychiatry 38: 24-29. (Pubitemid 40278643)
197. Kuhn R, Pagano A, Stoehr N, Vranesic I, Flor PJ, Lingenhöhl K, et al,. (2002). In vitro and in vivo characterization of MPEP, an allosteric modulator of the metabotropic glutamate receptor subtype 5: review article. Amino Acids 23: 207-211.
198. Lähdesmäki J, Sallinen J, MacDonald E, Kobilka BK, Fagerholm V, Scheinin M, (2002). Behavioral and neurochemical characterization of alpha(2A)-adrenergic receptor knockout mice. Neuroscience 113: 289-299. (Pubitemid 34786174)
199. Lakoff A, (2002). The mousetrap: managing the placebo effect in antidepressant trials. Mol Interv 2: 72-76.
200. Landgraf R, KeÃler MS, Bunck M, Murgatroyd C, Spengler D, Zimbelmann M, et al,. (2007). Candidate genes of anxiety-related behavior in HAB/LAB rats and mice: focus on vasopressin and glyoxalase-I. Neurosci Biobehav Rev 31: 89-102. (Pubitemid 44880077)
201. Lang PJ, Davis M, Ohman A, (2000). Fear and anxiety: animal models and human cognitive psychophysiology. J Affect Disord 61: 137-159. (Pubitemid 32119263)
202. Lara DR, (2010). Caffeine, mental health, and psychiatric disorders. Alzheimers Dis 20 (Suppl. 1): S239-S248.
203. Ledgerwood L, Richardson R, Cranney J, (2005). d-cycloserine facilitates extinction of learned fear: effects on reacquisition and generalized extinction. Biol Psychiatry 57: 841-847. (Pubitemid 40488352)
204. Lee C, Rodgers RJ, (1990). Antinociceptive effects of elevated plus-maze exposure: influence of opiate receptor manipulations. Psychopharmacology 102: 507-513. (Pubitemid 20379507)
205. Lee C, Parks GS, Civelli O, (2010). Anxiolytic effects of the MCH1R antagonist TPI 1361-17. J Mol Neurosci 43: 132-137.
206. Lehmann J, Feldon J, (2000). Long-term biobehavioral effects of maternal separation in the rat: consistent or confusing? Rev Neurosci 11: 383-408.
207. Leite JR, Seabra MDL, Sartori VA, Andreatini R, (1999). The video-recorded Stroop color-word test as a new model of experimentally-induced anxiety. Prog Neuropsychopharmacol Biol Psychiatry 23: 809-822. (Pubitemid 29416756)
208. Liebowitz MR, Fyer AJ, Gorman JM, Dillon D, Appleby IL, Levy G, et al,. (1984). Lactate provocation of panic attacks. I. Clinical and behavioral findings. Arch Gen Psychiatry 41: 764-770. (Pubitemid 14092254)
209. Liebowitz MR, Gorman JM, Fyer AJ, Levitt M, Dillon D, Levy G, et al,. (1985). Lactate provocation of panic attacks. II. Biochemical and physiological findings. Arch Gen Psychiatry 42: 709-719. (Pubitemid 15054616)
210. Line SJ, Barkus C, Coyle C, Jennings KA, Deacon RM, Lesch KP, et al,. (2011). Opposing alterations in anxiety and species-typical behaviours in serotonin transporter overexpressor and knockout mice. Eur Neuropsychopharmacol 21: 108-116.
211. Lister RG, (1987). The use of a plus-maze to measure anxiety in the mouse. Psychopharmacology (Berl) 92: 180-185. (Pubitemid 17072893)
212. Liu G, Cai G, Cai Y, Sheng Z, Jiang J, Mei Z, et al,. (2007). Reduced anxiety and depression-like behaviors in mice lacking GABA transporter subtype 1. Neuropsychopharmacology 32: 1531-1539. (Pubitemid 46920158)
213. Lopes FL, Azevedo TM, Imbiriba LA, Freire RC, ValenÃa AM, Caldirola D, et al,. (2009). Freezing reaction in panic disorder patients associated with anticipatory anxiety. Depress Anxiety 26: 917-921.
214. Lõpez-Aumatell R, Blázquez G, Gil L, Aguilar R, Cañete T, Giménez-Llort L, et al,. (2009). The Roman high- and low-avoidance rat strains differ in fear-potentiated startle and classical aversive conditioning. Psicothema 21: 27-32.
215. Lõpez-Muñoz F, Ucha-Udabe R, Alamo C, (2005). The history of barbiturates a century after their clinical introduction. Neuropsychiatr Dis Treat 1: 329-343.
216. Lucki I, Ward HR, Frazer A, (1989). Effect of 1-(m-chlorophenyl) piperazine and 1-(m-trifluoromethylphenyl)piperazine on locomotor activity. J Pharmacol Exp Ther 249: 155-164.
217. McAuley JD, Stewart AL, Webber ES, Cromwell HC, Servatius RJ, Pang KCH, (2009). Wistar-Kyoto rats as an animal model of anxiety vulnerability: support for a hypervigilance hypothesis. Behav Brain Res 204: 162-168.
218. McKinney WT, Bunney WE, (1969). Animal model of depression. I. Review of evidence: implications for research. Arch Gen Psychiatry 21: 240-248.
219. Markou A, Chiamulera C, Geyer MA, Tricklebank M, Steckler T, (2009). Removing obstacles in neuroscience drug discovery: the future path for animal models. Neuropsychopharmacology 34: 74-89.
220. Maron E, TÃμru I, Mäemets K, Sepp S, Vasar V, Shlik J, et al,. (2009). CCK-4-induced anxiety but not panic is associated with serum brain-derived neurotrophic factor in healthy subjects. J Psychopharmacol (Oxford) 23: 460-464.
221. Maron E, Kallassalu K, Tammiste A, Kolde R, Vilo J, TÃμru I, et al,. (2010). Peripheral gene expression profiling of CCK-4-induced panic in healthy subjects. Am J Med Genet B Neuropsychiatr Genet 153B: 269-274.
222. Matsuo M, Ayuse T, Oi K, Kataoka Y, (1997). Propofol produces anticonflict action by inhibiting 5-HT release in rat dorsal hippocampus. Neuroreport 8: 3087-3090. (Pubitemid 27421736)
223. Merali Z, Levac C, Anisman H, (2003). Validation of a simple, ethologically relevant paradigm for assessing anxiety in mice. Biol Psychiatry 54: 552-565. (Pubitemid 37289442)
224. Merikangas KR, (2003). Implications of genomics for public health: the role of genetic epidemiology. Cold Spring Harb Symp Quant Biol 68: 359-364. (Pubitemid 38955586)
225. Mickley GA, Kenmuir CL, McMullen CA, Yocom AM, Valentine EL, Dengler-Crish CM, et al,. (2004). Dynamic processing of taste aversion extinction in the brain. Brain Res 1016: 79-89. (Pubitemid 38834275)
226. Millan MJ, Brocco M, (2003). The Vogel conflict test: procedural aspects, gamma-aminobutyric acid, glutamate and monoamines. Eur J Pharmacol 463: 67-96. (Pubitemid 36205073)
227. Miller G, Holden C, (2010). Psychiatry. Proposed revisions to psychiatry's canon unveiled. Science 327: 770-771.
228. Millstein RA, Holmes A, (2007). Effects of repeated maternal separation on anxiety- and depression-related phenotypes in different mouse strains. Neurosci Biobehav Rev 31: 3-17. (Pubitemid 44880075)
229. Molinengo L, Ricci-Gamalero S, (1970). The 'staircase maze' and the 'simple staircase' in the analysis of the psychopharmacological action of CNS depressants. Pharmacology 4: 169-178.
230. Mombereau C, Kaupmann K, Gassmann M, Bettler B, van der Putten H, Cryan JF, (2005). Altered anxiety and depression-related behaviour in mice lacking GABAB(2) receptor subunits. Neuroreport 16: 307-310. (Pubitemid 40364596)
231. Mombereau C, Lhuillier L, Kaupmann K, Cryan JF, (2007). GABAB receptor-positive modulation-induced blockade of the rewarding properties of nicotine is associated with a reduction in nucleus accumbens DeltaFosB accumulation. J Pharmacol Exp Ther 321: 172-177. (Pubitemid 46456987)
232. Mongeau R, Marsden CA, (1997). Effect of central and peripheral administrations of cholecystokinin-tetrapeptide on panic-like reactions induced by stimulation of the dorsal periaqueductal grey area in the rat. Biol Psychiatry 42: 335-344. (Pubitemid 27380967)
233. Monn JA, Valli MJ, Massey SM, Wright RA, Salhoff CR, Johnson BG, et al,. (1997). Design, synthesis, and pharmacological characterization of (+)-2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylic acid (LY354740): a potent, selective, and orally active group 2 metabotropic glutamate receptor agonist possessing anticonvulsant and anxiolytic properties. J Med Chem 40: 528-537. (Pubitemid 27080033)
234. Moser PC, Tricklebank MD, Middlemiss DN, Mir AK, Hibert MF, Fozard JR, (1990). Characterization of MDL 73005EF as a 5-HT1A selective ligand and its effects in animal models of anxiety: comparison with buspirone, 8-OH-DPAT and diazepam. Br J Pharmacol 99: 343-349. (Pubitemid 20147530)
235. Murphy SE, (2010). Using functional neuroimaging to investigate the mechanisms of action of selective serotonin reuptake inhibitors (SSRIs). Curr Pharm Des 16: 1990-1997.
236. Murphy SE, Downham C, Cowen PJ, Harmer CJ, (2008). Direct effects of diazepam on emotional processing in healthy volunteers. Psychopharmacology (Berl) 199: 503-513.
237. Nardi AE, ValenÃa AM, Mezzasalma MA, Lopes FL, Nascimento I, Veras AB, et al,. (2006). 35% Carbon dioxide and breath-holding challenge tests in panic disorder: a comparison with spontaneous panic attacks. Depress Anxiety 23: 236-244. (Pubitemid 44147908)
238. Nardi AE, ValenÃa AM, Lopes FL, de-Melo-Neto VL, Freire RC, Veras AB, et al,. (2007). Caffeine and 35% carbon dioxide challenge tests in panic disorder. Hum Psychopharmacol 22: 231-240. (Pubitemid 46939280)
239. Nastiti K, Benton D, Brain PF, Haug M, (1991a). The effects of 5-HT receptor ligands on ultrasonic calling in mouse pups. Neurosci Biobehav Rev 15: 483-487.
240. Nastiti K, Benton D, Brain P, (1991b). The effects of compounds acting at the benzodiazepine receptor complex on the ultrasonic calling of mouse pups. Behav Pharmacol 2: 121-128.
241. Netto CF, Guimarães FS, (2004). Anxiogenic effect of cholecystokinin in the dorsal periaqueductal gray. Neuropsychopharmacology 29: 101-107. (Pubitemid 38068019)
242. Njung'e K, Handley SL, (1991). Evaluation of marble-burying behavior as a model of anxiety. Pharmacol Biochem Behav 38: 63-67.
243. Noirot E, (1972). Ultrasounds and maternal behavior in small rodents. Dev Psychobiol 5: 371-387.
244. Nutt DJ, Kessler RC, Alonso J, Benbow A, Lecrubier Y, Lépine J, et al,. (2007). Consensus statement on the benefit to the community of ESEMeD (European Study of the Epidemiology of Mental Disorders) survey data on depression and anxiety. J Clin Psychiatry 68 (Suppl. 2): 42-48. (Pubitemid 46333566)
245. O'Connor RM, Finger BC, Flor PJ, Cryan JF, (2010). Metabotropic glutamate receptor 7: at the interface of cognition and emotion. Eur J Pharmacol 639: 123-131.
246. Ohl F, Holsboer F, Landgraf R, (2001a). The modified hole board as a differential screen for behavior in rodents. Behav Res Methods Instrum Comput 33: 392-397. (Pubitemid 33594753)
247. Ohl F, Sillaber I, Binder E, Keck ME, Holsboer F, (2001b). Differential analysis of behavior and diazepam-induced alterations in C57BL/6N and BALB/c mice using the modified hole board test. J Psychiatr Res 35: 147-154. (Pubitemid 32672856)
248. O'Mahony SM, Hyland NP, Dinan TG, Cryan JF, (2010). Maternal separation as a model of brain-gut axis dysfunction. Psychopharmacology (Berl) 214: 71-88.
249. Onaivi ES, Martin BR, (1989). Neuropharmacological and physiological validation of a computer-controlled two-compartment black and white box for the assessment of anxiety. Prog Neuropsychopharmacol Biol Psychiatry 13: 963-976. (Pubitemid 19238705)
250. Owen EH, Logue SF, Rasmussen DL, Wehner JM, (1997). Assessment of learning by the Morris water task and fear conditioning in inbred mouse strains and F1 hybrids: implications of genetic background for single gene mutations and quantitative trait loci analyses. Neuroscience 80: 1087-1099. (Pubitemid 27359794)
251. Pape H, Pare D, (2010). Plastic synaptic networks of the amygdala for the acquisition, expression, and extinction of conditioned fear. Physiol Rev 90: 419-463.
252. Paré WP, (1994). Open field, learned helplessness, conditioned defensive burying, and forced-swim tests in WKY rats. Physiol Behav 55: 433-439. (Pubitemid 24088009)
253. Parsons RG, Davis M, (2011). Temporary disruption of fear-potentiated startle following PKMζ inhibition in the amygdala. Nat Neurosci 14: 295-296. doi:10.1038/nn.2745.
254. Paterson NE, Hanania T, (2010). The modified Geller-Seifter test in rats was insensitive to GABAB receptor positive modulation or blockade, or 5-HT1A receptor activation. Behav Brain Res 208: 258-264.
255. Paulus MP, Stein MB, (2006). An insular view of anxiety. Biol Psychiatry 60: 383-387. (Pubitemid 44215849)
256. Pellow S, Chopin P, File SE, Briley M, (1985). Validation of open: closed arm entries in an elevated plus-maze as a measure of anxiety in the rat. J Neurosci Methods 14: 149-167. (Pubitemid 16239568)
257. Perry W, Minassian A, Paulus MP, Young JW, Kincaid MJ, Ferguson EJ, et al,. (2009). A reverse-translational study of dysfunctional exploration in psychiatric disorders: from mice to men. Arch Gen Psychiatry 66: 1072-1080.
258. Phelps EA, LeDoux JE, (2005). Contributions of the amygdala to emotion processing: from animal models to human behavior. Neuron 48: 175-187. (Pubitemid 41476352)
259. Phillips JM, Siegel SJ, Shields AE, Patterson F, Gould TJ, Strasser AA, et al,. (2007). Translating basic science to improve pharmacotherapy for nicotine dependence. Nicotine Tob Res 9 (Suppl. 4): S583-S598.
260. Picazo O, Fernández-Guasti A, (1995). Anti-anxiety effects of progesterone and some of its reduced metabolites: an evaluation using the burying behavior test. Brain Res 680: 135-141.
261. Plotsky PM, Meaney MJ, (1993). Early, postnatal experience alters hypothalamic corticotropin-releasing factor (CRF) mRNA, median eminence CRF content and stress-induced release in adult rats. Brain Res Mol Brain Res 18: 195-200.
262. Pobbe RLH, Defensor EB, Pearson BL, Bolivar VJ, Blanchard DC, Blanchard RJ, (2010). General and social anxiety in the BTBR T+ tf/J mouse strain. Behav Brain Res 216: 446-451.
263. Pohl R, Ettedgui E, Bridges M, Lycaki H, Jimerson D, Kopin I, et al,. (1987). Plasma MHPG levels in lactate and isoproterenol anxiety states. Biol Psychiatry, 22: 1127-1136. (Pubitemid 17138306)
264. Prut L, Belzung C, (2003). The open field as a paradigm to measure the effects of drugs on anxiety-like behaviors: a review. Eur J Pharmacol 463: 3-33. (Pubitemid 36205070)
265. Raber J, (2007). Role of apolipoprotein e in anxiety. Neural Plast 2007: 91236. doi:10.1155/2007/91236. (Pubitemid 47261562)
266. Ramboz S, Oosting R, Amara DA, Kung HF, Blier P, Mendelsohn M, et al,. (1998). Serotonin receptor 1A knockout: an animal model of anxiety-related disorder. Proc Natl Acad Sci U S A 95: 14476-14481. (Pubitemid 28549392)
267. Randall LO, (1960). Pharmacology of methaminodiazepoxide. Dis Nerv Syst 21: 7-10.
268. Reijmers LG, Perkins BL, Matsuo N, Mayford M, (2007). Localization of a stable neural correlate of associative memory. Science 317: 1230-1233.
269. Ressler KJ, Rothbaum BO, Tannenbaum L, Anderson P, Graap K, Zimand E, et al,. (2004). Cognitive enhancers as adjuncts to psychotherapy: use of d-cycloserine in phobic individuals to facilitate extinction of fear. Arch Gen Psychiatry 61: 1136-1144. (Pubitemid 39463415)
270. Rex A, Voigt JP, Voits M, Fink H, (1998). Pharmacological evaluation of a modified open-field test sensitive to anxiolytic drugs. Pharmacol Biochem Behav 59: 677-683. (Pubitemid 28144209)
271. Rickels K, Csanalosi I, Chung HR, Case WG, Pereira-Ogan JA, Downing RW, (1974). Amitriptyline in anxious-depressed outpatients: a controlled study. Am J Psychiatry 131: 25-30.
272. Rickels K, Downing R, Schweizer E, Hassman H, (1993). Antidepressants for the treatment of generalized anxiety disorder. A placebo-controlled comparison of imipramine, trazodone, and diazepam. Arch Gen Psychiatry 50: 884-895. (Pubitemid 23330980)
273. Ripoll N, HascoÃt M, Bourin M, (2006). The four-plates test: anxiolytic or analgesic paradigm? Prog Neuropsychopharmacol Biol Psychiatry 30: 873-880. (Pubitemid 43795375)
274. Robichaud RC, Sledge KL, (1969). The effects of p-chlorophenylalanine on experimentally induced conflict in the rat. Life Sci 8: 965-969.
275. Rodgers R, (2010). Animal tests for anxiety. In:, Koob GF, Le Moal M, Thompson RF, (eds). Encyclopedia of Behavioral Neuroscience. Academic Press: Oxford, pp. 90-100.
276. Rodgers RJ, (1997). Animal models of 'anxiety': where next? Behav Pharmacol 8: 477-496, discussion 497-504. (Pubitemid 27504695)
277. Rodgers RJ, Cao BJ, Dalvi A, Holmes A, (1997). Animal models of anxiety: an ethological perspective. Braz J Med Biol Res 30: 289-304. (Pubitemid 127521025)
278. Roy-Byrne PP, Davidson KW, Kessler RC, Asmundson GJG, Goodwin RD, Kubzansky L, et al,. (2008). Anxiety disorders and comorbid medical illness. Gen Hosp Psychiatry 30: 208-225. (Pubitemid 351545834)
279. Rupprecht R, Rammes G, Eser D, Baghai TC, Schüle C, Nothdurfter C, et al,. (2009). Translocator protein (18 kD) as target for anxiolytics without benzodiazepine-like side effects. Science 325: 490-493.
280. Rupprecht R, Papadopoulos V, Rammes G, Baghai TC, Fan J, Akula N, et al,. (2010). Translocator protein (18 kDa) (TSPO) as a therapeutic target for neurological and psychiatric disorders. Nat Rev Drug Discov 9: 971-988.
281. Salomé N, Viltart O, Darnaudéry M, Salchner P, Singewald N, Landgraf R, et al,. (2002). Reliability of high and low anxiety-related behaviour: influence of laboratory environment and multifactorial analysis. Behav Brain Res 136: 227-237. (Pubitemid 35246408)
282. Salomons AR, van Luijk JAK, Reinders NR, Kirchhoff S, Arndt SS, Ohl F, (2010a). Identifying emotional adaptation: behavioural habituation to novelty and immediate early gene expression in two inbred mouse strains. Genes Brain Behav 9: 1-10.
283. Salomons AR, Kortleve T, Reinders NR, Kirchhoff S, Arndt SS, Ohl F, (2010b). Susceptibility of a potential animal model for pathological anxiety to chronic mild stress. Behav Brain Res 209: 241-248.
284. Sánchez C, (2003). Stress-induced vocalisation in adult animals. A valid model of anxiety? Eur J Pharmacol 463: 133-143. (Pubitemid 36205076)
285. Sánchez C, Meier E, (1997). Behavioral profiles of SSRIs in animal models of depression, anxiety and aggression. Are they all alike? Psychopharmacology (Berl) 129: 197-205. (Pubitemid 27085389)
286. Sanford LD, Fang J, Tang X, (2003a). Sleep after differing amounts of conditioned fear training in BALB/cJ mice. Behav Brain Res 147: 193-202. (Pubitemid 37491427)
287. Sanford LD, Yang L, Tang X, (2003b). Influence of contextual fear on sleep in mice: a strain comparison. Sleep 26: 527-540. (Pubitemid 39610644)
288. Santarelli L, Gobbi G, Blier P, Hen R, (2002). Behavioral and physiologic effects of genetic or pharmacologic inactivation of the substance P receptor (NK1). J Clin Psychiatry 63 (Suppl. 11): 11-17. (Pubitemid 35435003)
289. Santarelli L, Saxe M, Gross C, Surget A, Battaglia F, Dulawa S, et al,. (2003). Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants. Science 301: 805-809. (Pubitemid 36962615)
290. Sass SM, Heller W, Stewart JL, Silton RL, Edgar JC, Fisher JE, et al,. (2010). Time course of attentional bias in anxiety: emotion and gender specificity. Psychophysiology 47: 247-259.
291. Sato T, (2005). The internal conflict model: a theoretical framework for integration. Humanist Psychol 33: 33-44.
292. Savignac HM, Dinan TG, Cryan JF, (2011). Resistance to early-life stress in mice: effects of genetic background and stress duration. Front Behav Neurosci 5: DOI: 10.3389/fnbeh.2011.00013.
293. Scattoni ML, Crawley J, Ricceri L, (2009). Ultrasonic vocalizations: a tool for behavioural phenotyping of mouse models of neurodevelopmental disorders. Neurosci Biobehav Rev 33: 508-515.
294. Schiller D, Delgado MR, (2010). Overlapping neural systems mediating extinction, reversal and regulation of fear. Trends Cogn Sci (Regul Ed) 14: 268-276.
295. Schiller D, Monfils M, Raio CM, Johnson DC, Ledoux JE, Phelps EA, (2010). Preventing the return of fear in humans using reconsolidation update mechanisms. Nature 463: 49-53.
296. Schmitt U, Hiemke C, (1998). Combination of open field and elevated plus-maze: a suitable test battery to assess strain as well as treatment differences in rat behavior. Prog Neuropsychopharmacol Biol Psychiatry 22: 1197-1215. (Pubitemid 28511595)
297. Schramm NL, McDonald MP, Limbird LE, (2001). The alpha(2a)-adrenergic receptor plays a protective role in mouse behavioral models of depression and anxiety. J Neurosci 21: 4875-4882. (Pubitemid 32565645)
298. Sekiyama K, Hashimoto O, Ushiro Y, Adachi C, Kikusui T, Tanemura K, et al,. (2009). Abnormalities in aggression and anxiety in transgenic mice overexpressing activin E. Biochem Biophys Res Commun 385: 319-323.
299. Shekhar A, Keim SR, Simon JR, McBride WJ, (1996). Dorsomedial hypothalamic GABA dysfunction produces physiological arousal following sodium lactate infusions. Pharmacol Biochem Behav 55: 249-256. (Pubitemid 26414107)
300. Shekhar A, Johnson PL, Fitz SD, Nakazato A, Chaki S, Steckler T, et al,. (2010). A selective, non-peptide CRF receptor 1 antagonist prevents sodium lactate-induced acute panic-like responses. Int J Neuropsychopharmacol 14: 355-365.
301. Shepherd JK, Grewal SS, Fletcher A, Bill DJ, Dourish CT, (1994). Behavioural and pharmacological characterisation of the elevated 'zero-maze' as an animal model of anxiety. Psychopharmacology (Berl) 116: 56-64. (Pubitemid 24279597)
302. Sherif F, Oreland L, (1995). Effect of the GABA-transaminase inhibitor vigabatrin on exploratory behaviour in socially isolated rats. Behav Brain Res 72: 135-140.
303. Shibata S, Yamashita K, Yamamoto E, Ozaki T, Ueki S, (1989). Effects of benzodiazepine and GABA antagonists on anticonflict effects of antianxiety drugs injected into the rat amygdala in a water-lick suppression test. Psychopharmacology (Berl) 98: 38-44. (Pubitemid 19117341)
304. Shimazaki T, Yoshimizu T, Chaki S, (2006). Melanin-concentrating hormone MCH1 receptor antagonists: a potential new approach to the treatment of depression and anxiety disorders. CNS Drugs 20: 801-811. (Pubitemid 44484244)
305. Shorter E, Tyrer P, (2003). Separation of anxiety and depressive disorders: blind alley in psychopharmacology and classification of disease. BMJ 327: 158-160. (Pubitemid 36876213)
306. Sidman M, (1953). Avoidance conditioning with brief shock and no exteroceptive warning signal. Science 118: 157-158.
307. Sierra-Mercado D, Padilla-Coreano N, Quirk GJ, (2011). Dissociable roles of prelimbic and infralimbic cortices, ventral hippocampus, and basolateral amygdala in the expression and extinction of conditioned fear. Neuropsychopharmacology 36: 529-538.
308. Sigurdsson T, DoyÃre V, Cain CK, LeDoux JE, (2007). Long-term potentiation in the amygdala: a cellular mechanism of fear learning and memory. Neuropharmacology 52: 215-227. (Pubitemid 46026826)
309. Sillaber I, Panhuysen M, Henniger MSH, Ohl F, Kühne C, Pütz B, et al,. (2008). Profiling of behavioral changes and hippocampal gene expression in mice chronically treated with the SSRI paroxetine. Psychopharmacology (Berl) 200: 557-572.
310. Simiand J, Keane PE, Morre M, (1984). The staircase test in mice: a simple and efficient procedure for primary screening of anxiolytic agents. Psychopharmacology (Berl) 84: 48-53. (Pubitemid 14032207)
311. Singewald N, (2007). Altered brain activity processing in high-anxiety rodents revealed by challenge paradigms and functional mapping. Neurosci Biobehav Rev 31: 18-40. (Pubitemid 44880071)
312. Sluyter F, Korte SM, Bohus B, Van Oortmerssen GA, (1996). Behavioral stress response of genetically selected aggressive and nonaggressive wild house mice in the shock-probe/defensive burying test. Pharmacol Biochem Behav 54: 113-116. (Pubitemid 26143097)
313. Sluyter F, Korte SM, Van Baal GC, De Ruiter AJ, Van Oortmerssen GA, (1999). Y chromosomal and sex effects on the behavioral stress response in the defensive burying test in wild house mice. Physiol Behav 67: 579-585. (Pubitemid 29488538)
314. Soubríe P, Kulkarni S, Simon P, Boissier JR, (1975). [Effects of antianxiety drugs on the food intake in trained and untrained rats and mice (author's transl)]. Psychopharmacologia 45: 203-210.
315. Spencer CM, Alekseyenko O, Serysheva E, Yuva-Paylor LA, Paylor R, (2005). Altered anxiety-related and social behaviors in the Fmr1 knockout mouse model of fragile X syndrome. Genes Brain Behav 4: 420-430. (Pubitemid 41428518)
316. Spooren W, Gasparini F, (2004). mGlu5 receptor antagonists: a novel class of anxiolytics? Drug News Perspect 17: 251-257. (Pubitemid 38987367)
317. Spooren WP, Vassout A, Neijt HC, Kuhn R, Gasparini F, Roux S, et al,. (2000). Anxiolytic-like effects of the prototypical metabotropic glutamate receptor 5 antagonist 2-methyl-6-(phenylethynyl)pyridine in rodents. J Pharmacol Exp Ther 295: 1267-1275.
318. Spooren WPJ, Schoeffter P, Gasparini F, Kuhn R, Gentsch C, (2002). Pharmacological and endocrinological characterisation of stress-induced hyperthermia in singly housed mice using classical and candidate anxiolytics (LY314582, MPEP and NKP608). Eur J Pharmacol 435: 161-170. (Pubitemid 34131696)
319. Sramek JJ, Zarotsky V, Cutler NR, (2002). Generalised anxiety disorder: treatment options. Drugs 62: 1635-1648. (Pubitemid 34848371)
320. Stachowicz K, Brañski P, KÅak K, van der Putten H, Cryan JF, Flor PJ, et al,. (2008). Selective activation of metabotropic G-protein-coupled glutamate 7 receptor elicits anxiolytic-like effects in mice by modulating GABAergic neurotransmission. Behav Pharmacol 19: 597-603.
321. Steckler T, Stein MB, Holmes A, (2008). Developing novel anxiolytics: improving preclinical detection and clinical assesment. In:, McArthur RA, Borsini F, (eds). Animals and Translational Models for CNS Drug Discovery. Academic Press: San Diego, CA, pp. 117-132.
322. StefaÅski R, PaÅejko W, Kostowski W, PÅaznik A, (1992). The comparison of benzodiazepine derivatives and serotonergic agonists and antagonists in two animal models of anxiety. Neuropharmacology 31: 1251-1258.
323. Steimer T, Driscoll P, (2003). Divergent stress responses and coping styles in psychogenetically selected Roman high-(RHA) and low-(RLA) avoidance rats: behavioural, neuroendocrine and developmental aspects. Stress 6: 87-100. (Pubitemid 36681959)
324. Steimer T, la Fleur S, Schulz PE, (1997). Neuroendocrine correlates of emotional reactivity and coping in male rats from the Roman high (RHA/Verh)- and low (RLA/Verh)-avoidance lines. Behav Genet 27: 503-512. (Pubitemid 28098958)
325. Sternbach LH, (1979). The benzodiazepine story. J Med Chem 22: 1-7. (Pubitemid 9041283)
326. Stork O, Yamanaka H, Stork S, Kume N, Obata K, (2003). Altered conditioned fear behavior in glutamate decarboxylase 65 null mutant mice. Genes Brain Behav 2: 65-70. (Pubitemid 36717651)
327. Takahashi LK, (2001). Role of CRF1 and CRF2 receptors in fear and anxiety. Neurosci Biobehav Rev 25: 627-636. (Pubitemid 34136892)
328. Tarantino LM, Bucan M, (2000). Dissection of behavior and psychiatric disorders using the mouse as a model. Hum Mol Genet 9: 953-965. (Pubitemid 30216107)
329. Taylor DP, Moon SL, (1991). Buspirone and related compounds as alternative anxiolytics. Neuropeptides 19 (Suppl.): 15-19.
330. Tecott LH, (2003). The genes and brains of mice and men. Am J Psychiatry 160: 646-656. (Pubitemid 41079595)
331. Thoeringer CK, Erhardt A, Sillaber I, Mueller MB, Ohl F, Holsboer F, et al,. (2010). Long-term anxiolytic and antidepressant-like behavioural effects of tiagabine, a selective GABA transporter-1 (GAT-1) inhibitor, coincide with a decrease in HPA system activity in C57BL/6 mice. J Psychopharmacol (Oxford) 24: 733-743.
332. Thomas A, Burant A, Bui N, Graham D, Yuva-Paylor LA, Paylor R, (2009). Marble burying reflects a repetitive and perseverative behavior more than novelty-induced anxiety. Psychopharmacology (Berl) 204: 361-373.
333. TÃμru I, Aluoja A, VÃμhma U, Raag M, Vasar V, Maron E, et al,. (2010). Associations between personality traits and CCK-4-induced panic attacks in healthy volunteers. Psychiatry Res 178: 342-347.
334. Treit D, Pinel JP, Fibiger HC, (1981). Conditioned defensive burying: a new paradigm for the study of anxiolytic agents. Pharmacol Biochem Behav 15: 619-626. (Pubitemid 11015566)
335. Treit D, Engin E, McEown K, (2010). Animal models of anxiety and anxiolytic drug action. In:, Stein MB, Steckler T, (eds). Behavioral Neurobiology of Anxiety and Its Treatment. Current Topics in Behavioral Neurosciences. Academic Press: Waltham MA, pp. 121-160.
336. Trullas R, Skolnick P, (1993). Differences in fear motivated behaviors among inbred mouse strains. Psychopharmacology (Berl) 111: 323-331. (Pubitemid 23165262)
337. Tulen JH, Moleman P, van Steenis HG, Boomsma F, (1989). Characterization of stress reactions to the Stroop color word test. Pharmacol Biochem Behav 32: 9-15. (Pubitemid 19125909)
338. Umehara F, Mishima K, Egashira N, Ogata A, Iwasaki K, Fujiwara M, (2006). Elevated anxiety-like and depressive behavior in desert hedgehog knockout male mice. Behav Brain Res 174: 167-173. (Pubitemid 44397191)
339. Van Bogaert M, Oosting R, Toth M, Groenink L, van Oorschot R, Olivier B, (2006). Effects of genetic background and null mutation of 5-HT1A receptors on basal and stress-induced body temperature: modulation by serotonergic and GABAA-ergic drugs. Eur J Pharmacol 550: 84-90. (Pubitemid 44572273)
340. Varty GB, Cohen-Williams ME, Morgan CA, Pylak U, Duffy RA, Lachowicz JE, et al,. (2002). The gerbil elevated plus-maze II: anxiolytic-like effects of selective neurokinin NK1 receptor antagonists. Neuropsychopharmacology 27: 371-379. (Pubitemid 35253785)
341. Varty GB, Grilli M, Forlani A, Fredduzzi S, Grzelak ME, Guthrie DH, et al,. (2005). The antinociceptive and anxiolytic-like effects of the metabotropic glutamate receptor 5 (mGluR5) antagonists, MPEP and MTEP, and the mGluR1 antagonist, LY456236, in rodents: a comparison of efficacy and side-effect profiles. Psychopharmacology 179: 207-217. (Pubitemid 40576708)
342. Vaswani M, Linda FK, Ramesh S, (2003). Role of selective serotonin reuptake inhibitors in psychiatric disorders: a comprehensive review. Prog Neuropsychopharmacol Biol Psychiatry 27: 85-102. (Pubitemid 36131110)
343. Vendruscolo LF, Takahashi RN, Brüske GR, Ramos A, (2003). Evaluation of the anxiolytic-like effect of NKP608, a NK1-receptor antagonist, in two rat strains that differ in anxiety-related behaviors. Psychopharmacology (Berl) 170: 287-293. (Pubitemid 37491608)
344. Vetter DE, Li C, Zhao L, Contarino A, Liberman MC, Smith GW, et al,. (2002). Urocortin-deficient mice show hearing impairment and increased anxiety-like. Behavior Nat Genet 31: 363-369. (Pubitemid 35154444)
345. Vinkers CH, van Bogaert MJV, Klanker M, Korte SM, Oosting R, Hanania T, et al,. (2008). Translational aspects of pharmacological research into anxiety disorders: the stress-induced hyperthermia (SIH) paradigm. Eur J Pharmacol 585: 407-425.
346. Vinkers CH, Cryan JF, Olivier B, Groenink L, (2010). Elucidating GABAA and GABAB receptor functions in anxiety using the stress-induced hyperthermia paradigm: a review. Open Pharmacol J 4: 1-14.
347. Vogel JR, Beer B, Clody DE, (1971). A simple and reliable conflict procedure for testing anti-anxiety agents. Psychopharmacologia 21: 1-7.
348. Voigt J, Hörtnagl H, Rex A, van Hove L, Bader M, Fink H, (2005). Brain angiotensin and anxiety-related behavior: the transgenic rat TGR(ASrAOGEN)680. Brain Res 1046: 145-156. (Pubitemid 40775884)
349. VÃμikar V, KÃμks S, Vasar E, Rauvala H, (2001). Strain and gender differences in the behavior of mouse lines commonly used in transgenic studies. Physiol Behav 72: 271-281. (Pubitemid 32184818)
350. Wacker DA, Miller KJ, (2008). Agonists of the serotonin 5-HT2C receptor: preclinical and clinical progression in multiple diseases. Curr Opin Drug Discov Devel 11: 438-445. (Pubitemid 351950839)
351. Wesolowska A, Nikiforuk A, Stachowicz K, Tatarczynska E, (2006). Effect of the selective 5-HT7 receptor antagonist SB 269970 in animal models of anxiety and depression. Neuropharmacology 51: 578-586. (Pubitemid 44215962)
352. WieroÅska JM, Stachowicz K, PaÅucha-Poniewiera A, Acher F, BraÅski P, Pilc A, (2010). Metabotropic glutamate receptor 4 novel agonist LSP1-2111 with anxiolytic, but not antidepressant-like activity, mediated by serotonergic and GABAergic systems. Neuropharmacology 59: 627-634.
353. Wigger A, Neumann ID, (1999). Periodic maternal deprivation induces gender-dependent alterations in behavioral and neuroendocrine responses to emotional stress in adult rats. Physiol Behav 66: 293-302. (Pubitemid 29206522)
354. Wiley JL, Compton AD, Porter JH, (1993). Effects of four antipsychotics on punished responding in rats. Pharmacol Biochem Behav 45: 263-267.
355. Wilks LJ, File SE, (1988). Evidence for simultaneous anxiolytic and aversive effects several hours after administration of sodium phenobarbitone to the rat. Neuropsychobiology 19: 86-89.
356. Williams JM, Mathews A, MacLeod C, (1996). The emotional Stroop task and psychopathology. Psychol Bull 120: 3-24. (Pubitemid 126447646)
357. Witkin JM, (2008). Animal models of obsessive-compulsive disorder. Curr Protoc Neurosci, Chapter 9:Unit 9.30.
358. Wong M, Licinio J, (2004). From monoamines to genomic targets: a paradigm shift for drug discovery in depression. Nat Rev Drug Discov 3: 136-151. (Pubitemid 38239775)
359. Wong DT, Perry KW, Bymaster FP, (2005). Case history: the discovery of fluoxetine hydrochloride (Prozac). Nat Rev Drug Discov 4: 764-774. (Pubitemid 43090497)
360. Wu L, Ko SW, Toyoda H, Zhao M, Xu H, Vadakkan KI, et al,. (2007). Increased anxiety-like behavior and enhanced synaptic efficacy in the amygdala of GluR5 knockout mice. PLoS ONE 2: e167.
361. Yamamoto Y, Akiyoshi J, Kiyota A, Katsuragi S, Tsutsumi T, Isogawa K, et al,. (2000). Increased anxiety behavior in OLETF rats without cholecystokinin-A receptor. Brain Res Bull 53: 789-792. (Pubitemid 32120284)
362. Yasoshima Y, Yamamoto T, (2005). Effects of midazolam on the expression of conditioned taste aversion in rats. Brain Res 1043: 115-123. (Pubitemid 40603378)
363. Yeragani VK, Pohl R, Balon R, Rainey JM, Berchou R, Ortiz A, (1988). Sodium lactate infusions after treatment with tricyclic antidepressants: behavioral and physiological findings. Biol Psychiatry 24: 767-774.
364. Yeragani VK, Pohl R, Bär K, Chokka P, Tancer M, (2007). Exaggerated beat-to-beat R amplitude variability in patients with panic disorder after intravenous isoproterenol. Neuropsychobiology 55: 213-218. (Pubitemid 47525242)
365. Yilmazer-Hanke DM, Faber-Zuschratter H, Linke R, Schwegler H, (2002). Contribution of amygdala neurons containing peptides and calcium-binding proteins to fear-potentiated startle and exploration-related anxiety in inbred Roman high- and low-avoidance rats. Eur J Neurosci 15: 1206-1218. (Pubitemid 35463621)
366. Young EA, Liberzon I, (2002). Stress and anxiety disorders. In:, Pfaff DW, Arnold AP, Fahrbach SE, Etgen AM, Rubin RT, (eds). Hormones, Brain and Behavior. Academic Press: San Diego, CA, pp. 443-465.
367. Zanoveli JM, Netto CF, Guimarães FS, Zangrossi H, (2004). Systemic and intra-dorsal periaqueductal gray injections of cholecystokinin sulfated octapeptide (CCK-8s) induce a panic-like response in rats submitted to the elevated T-maze. Peptides 25: 1935-1941. (Pubitemid 39389188)
368. Zhao L, Kim KW, Ikeda Y, Anderson KK, Beck L, Chase S, et al,. (2008). Central nervous system-specific knockout of steroidogenic factor 1 results in increased anxiety-like behavior. Mol Endocrinol 22: 1403-1415. (Pubitemid 351787000)
369. Zwanzger P, Jarry H, Eser D, Padberg F, Baghai T, Schule C, et al,. (2003). Plasma gamma-amino-butyric acid (GABA) levels in cholecystokinine- tetrapeptide (CCK-4) induced anxiety. J Neural Transm 110: 313-316. (Pubitemid 36359694)
370. Zwanzger P, Eser D, Romeo E, di Michele F, Baghai TC, Pasini A, et al,. (2009). Changes in CCK-4 induced panic after treatment with the GABA-reuptake inhibitor tiagabine are associated with an increase in 3alpha,5alpha- tetrahydrodeoxycorticosterone concentrations. Psychoneuroendocrinology 34: 1586-1589.